Pre-earnings brief
Reports
Tue, Oct 27, 2026
Est. EPS
—
Est. revenue
—
Implied move
±8.4%
EPS beat rate
75%
Chemed Corporation operates in the health care sector, primarily providing hospice and palliative care services. As a key player in health care services, its performance is closely tied to trends in aging populations and the demand for end-of-life care.
Last quarter
In Q2 2026, Chemed reported an EPS of $6.06, exceeding expectations by 18.36%. The stock reacted positively, gaining 1.63% the following day.
EPS beat streak
2Q
EPS beat rate
75%
Avg EPS surprise
+4.42%
Avg 1-day reaction
+0.55%
Analysts are cautiously optimistic about Chemed's upcoming earnings, given its recent strong performance. However, the lack of specific guidance raises some uncertainty.
Bull case
If Chemed continues its trend of beating EPS estimates, it could signal strong operational efficiency and effective cost management.
Bear case
Conversely, if the company fails to meet expectations or shows signs of slowing growth, it could lead to a negative market reaction.
The print will turn on these.
Q1
What will the EPS be this quarter, and will it continue the trend of beating estimates?
Given Chemed's recent performance, a strong EPS could reinforce investor confidence and drive the stock higher.
Q2
How is the company addressing potential challenges in the hospice care market?
Understanding management's strategy in a competitive landscape will be crucial for assessing future growth prospects.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±10.3%
Why consensus could be wrong
The Street may underestimate Chemed's ability to maintain its growth trajectory despite potential market challenges, particularly in hospice care.
Supporting evidence
Chemed has consistently beaten EPS estimates in recent quarters, suggesting strong management execution.
The options market is pricing a significant move, indicating that investors expect a notable reaction to the earnings report.
Key risk
If EPS comes in below $5.80, it could raise serious concerns about the company's growth prospects.
Pre-commit to what would confirm each case.
The market is debating whether Chemed can sustain its recent growth momentum in a challenging health care environment.
Bull confirmed if
An EPS of $6.50 or higher would confirm the bull case and suggest strong operational performance.
Bear confirmed if
An EPS below $5.80 could confirm the bear case, indicating potential issues in growth or profitability.
What the market is pricing for the move.
Implied Move
±8.22%
Historical Avg
±0.9%
The options market is pricing in a significant potential move, indicating that investors expect volatility around the earnings report.
Options are pricing ±8.4% while CHE has averaged ±0.9% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
21.7%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.0M
2,000 sh
1 insider
Net
$1.0M
Net selling
Most Active Insiders· 1 open-market trade
$1.0M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
106.50%
of float
Insider
1.94%
of float
Holders
699
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
1,484,282 sh · $744.3M
11.36%
11.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Chemed beats expectations, history suggests a potential stock increase of around 0.84%, confirming strong operational performance.
In line / cautious
If results are in line but cautious commentary is provided, the stock may react neutrally, reflecting uncertainty.
Miss
A miss could lead to a decline of about 0.33%, indicating investor disappointment and concerns about future growth.
The lines on the call that would change the story.
Recent Transactions
Sep 28, 2026 · @ $513.45
2,000 sh
$1.0M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
AQR Capital Management, LLC
972,474 sh · $487.6M
7.44%
134.0%
Vanguard Portfolio Management LLC
787,068 sh · $394.7M
6.02%
-3.5%
Vanguard Capital Management LLC
604,420 sh · $303.1M
4.62%
-5.0%
Acadian Asset Management. LLC
453,238 sh · $227.3M
3.47%
47.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.